Adenoviral vectors coated with cationic PEG derivatives for intravaginal vaccination against HIV-1

Biomaterials

Volumn 35, Issue 27, 2014, Pages 7896-7908

  Xie, Zhaolu ^a   Ji, Zhonghua ^a   Zhang, Zhirong ^a   Gong, Tao ^a   Sun, Xun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Adenovirus; Cationic PEG derivative; Immune response; Intravaginal immunization; Mucus

Indexed keywords

ANTIGENS; BODY FLUIDS; GENE EXPRESSION; IMMUNE SYSTEM; IMMUNIZATION; POLYMERS;

ADENOVIRUS; HYDROPHILIC SURFACES; IMMUNE RESPONSE; MOLECULAR COMPOSITIONS; MUCOSAL IMMUNE RESPONSE; MUCUS; PHYSICAL ADSORPTION; POLYETHYLENE GLYCOL (PEG);

PLASTIC COATINGS;

ADENOVIRUS VECTOR; APC; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MACROGOL; CATION; EPITOPE; GREEN FLUORESCENT PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MACROGOL DERIVATIVE;

ADSORPTION; ANIMAL EXPERIMENT; ARTICLE; COATED PARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VAGINAL LAVAGE; ADENOVIRIDAE; ANIMAL; BLOOD; CD4+ T LYMPHOCYTE; CHEMISTRY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIFFUSION; EPITHELIUM CELL; GENE VECTOR; GENETIC RECOMBINATION; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; INTRAVAGINAL DRUG ADMINISTRATION; METABOLISM; MUCUS; PARTICLE SIZE; STATIC ELECTRICITY; SYNTHESIS; VACCINATION; VAGINA;

ADENOVIRIDAE; ADMINISTRATION, INTRAVAGINAL; ANIMALS; CATIONS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DIFFUSION; EPITHELIAL CELLS; EPITOPES; FEMALE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; HUMANS; MICE; MUCUS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RECOMBINATION, GENETIC; STATIC ELECTRICITY; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; VACCINATION; VAGINA;

EID: 84903474294     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.056     Document Type: Article

References (54)

1. UNAIDS 2013 GLOBAL FACT SHEET http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/20130923_FactSheet_Global_en.pdf.
2. Pinto A., Fitzgerald J., Gao G., Wilson J., Ertl H. Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector. Vaccine 2004, 22:697-703.
3. Bomsel M., Tudor D., Drillet A.-S., Alfsen A., Ganor Y., Roger M.-G., et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269-280.
4. Borges O., Borchard G. Mucosal vaccination: opportunities and challenges. Novel immune potentiators and delivery technologies for next generation vaccines 2013, 65-80. Springer. M. Singh (Ed.).
5. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012, 12:592-605.
6. Vajdy M., Gardner J., Neidleman J., Cuadra L., Greer C., Perri S., et al. Human immunodeficiency virus type 1 Gag-Specific vaginal immunity and Protection after local immunizations with Sindbis virus-based Replicon particles. JInfect Dis 2001, 184:1613-1616.
7. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. JVirol 2003, 77:8729-8735.
8. Yang Z.-y., Wyatt L.S., Kong W.-p., Moodie Z., Moss B., Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. JVirol 2003, 77:799-803.
9. Casimiro D.R., Chen L., Fu T.-M., Evans R.K., Caulfield M.J., Davies M.-E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. JVirol 2003, 77:6305-6313.
10. Barouch D.H., Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005, 16:149-156.
11. Xiang Z., Gao G., Reyes-Sandoval A., Li Y., Wilson J., Ertl H. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. JVirol 2003, 77:10780-10789.
12. Zhu Q., Thomson C., Rosenthal K., McDermott M., Collins S., Gauldie J. Immunization with adenovirus at the large intestinal mucosa as an effective vaccination strategy against sexually transmitted viral infection. Mucosal Immunol 2008, 1:78-88.
13. Xiang Z., Ertl H.C. Induction of mucosal immunity with a replication-defective adenoviral recombinant. Vaccine 1999, 17:2003-2008.
14. de Souza A.P.D., Haut L.H., Silva R., Ferreira S.I., Zanetti C.R., Ertl H.C., et al. Genital CD8+ T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus. Vaccine 2007, 25:109-116.
15. Vajdy M. Current efforts on generation of optimal immune responses against HIV through mucosal immunisations. Drugs R D 2006, 7:267-288.
16. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
17. Zaman M., Chandrudu S., Toth I. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res 2013, 3:100-109.
18. Yu M., Vajdy M. Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther 2010, 10:1181-1195.
19. Lai S.K., Wang Y.-Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009, 61:158-171.
20. Ensign L.M., Schneider C., Suk J.S., Cone R., Hanes J. Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv Mater 2012, 24:3887-3894.
21. Wang Y.Y., Lai S.K., Suk J.S., Pace A., Cone R., Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl 2008, 47:9726-9729.
22. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.-Y., Cone R., et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 2007, 104:1482-1487.
23. Tang B.C., Dawson M., Lai S.K., Wang Y.-Y., Suk J.S., Yang M., et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci USA 2009, 106:19268-19273.
24. Cu Y., Booth C.J., Saltzman W.M. Invivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. JControl Release 2011, 156:258-264.
25. Zeng Q., Han J., Zhao D., Gong T., Zhang Z., Sun X. Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus. Int J Nanomed 2012, 7:985-997.
26. Fichorova R.N., Rheinwald J.G., Anderson D.J. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol Reprod 1997, 57:847-855.
27. Lautenschläger C., Schmidt C., Lehr C.-M., Fischer D., Stallmach A. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur J Pharm Biopharm 2013, 85:578-586.
28. Norris D.A., Sinko P.J. Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin. JAppl Polym Sci 1997, 63:1481-1492.
29. Shen H., Goldberg E., Saltzman W.M. Gene expression and mucosal immune responses after vaginal DNA immunization in mice using a controlled delivery matrix. JControl Release 2003, 86:339-348.
30. Woodrow K.A., Cu Y., Booth C.J., Saucier-Sawyer J.K., Wood M.J., Saltzman W.M. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009, 8:526-533.
31. Lin S.-W., Hensley S.E., Tatsis N., Lasaro M.O., Ertl H.C. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. JClin Invest 2007, 117:3958.
32. Dai B., Yang L., Yang H., Hu B., Baltimore D., Wang P. HIV-1 gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci USA 2009, 106:20382-20387.
33. Whaley K.J., Hanes J., Shattock R., Cone R.A., Friend D.R. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res 2010, 88:S55-S66.
34. Ensign L.M., Tang B.C., Wang Y.-Y., Terence A.T., Hoen T., Cone R., et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med 2012, 4. 138ra79-ra79.
35. Kim H.-D., Jin J.-J., Maxwell J.A., Fukuchi K.-i. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett 2007, 112:30-38.
36. Wegmann F., Gartlan K.H., Harandi A.M., Brinckmann S.A., Coccia M., Hillson W.R., et al. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol 2012, 30:883-888.
37. Li M., Jiang Y., Xu C., Zhang Z., Sun X. Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant. Int J Nanomed 2013, 8:1843.
38. Janes H., Frahm N., DeCamp A., Rolland M., Gabriel E., Wolfson J., et al. MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. PLoS One 2012, 7:e43396.
39. Johnston M.I., Fauci A.S. An HIV vaccine-challenges and prospects. NEngl J Med 2008, 359:888-890.
40. Cohen Y.Z., Dolin R. Novel HIV vaccine strategies: overview and perspective. Ther Adv Vaccines 2013, 1:99-112.
41. Yang M., Lai S.K., Wang Y.Y., Zhong W., Happe C., Zhang M., et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew Chem Int Ed Engl 2011, 50:2597-2600.
42. Lai S.K., Wang Y.-Y., Wirtz D., Hanes J. Micro-and macrorheology of mucus. Adv Drug Deliv Rev 2009, 61:86-100.
43. Lai S.K., Wang Y.-Y., Cone R., Wirtz D., Hanes J. Altering mucus rheology to "solidify" human mucus at the nanoscale. PLoS One 2009, 4:e4294.
44. Olmsted S.S., Padgett J.L., Yudin A.I., Whaley K.J., Moench T.R., Cone R.A. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 2001, 81:1930-1937.
45. Saltzman W.M., Radomsky M.L., Whaley K.J., Cone R.A. Antibody diffusion in human cervical mucus. Biophys J 1994, 66:508-515.
46. Tutykhina I.L., Logunov D.Y., Shcherbinin D.N., Shmarov M.M., Tukhvatulin A.I., Naroditsky B.S., et al. Development of adenoviral vector-based mucosal vaccine against influenza. JMol Med Berl 2011, 89:331-341.
47. Tatsis N., Fitzgerald J.C., Reyes-Sandoval A., Harris-McCoy K.C., Hensley S.E., Zhou D., et al. Adenoviral vectors persist invivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007, 110:1916-1923.
48. Byers A.M., Kemball C.C., Moser J.M., Lukacher A.E. Cutting edge: rapid invivo CTL activity by polyoma virus-specific effector and memory CD8+ T cells. JImmunol 2003, 171:17-21.
49. Chen J., Wu Q., Yang P., Hsu H.-C., Mountz J.D. Determination of specific CD4 and CD8 T cell epitopes after AAV2-and AAV8-hF. IX gene therapy. Mol Ther 2006, 13:260-269.
50. Tritel M., Stoddard A.M., Flynn B.J., Darrah P.A., Wu C.-y., Wille U., et al. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. JImmunol 2003, 171:2538-2547.
51. Wortmann A., Vöhringer S., Engler T., Corjon S., Schirmbeck R., Reimann J., et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther 2008, 16:154-162.
52. Lemiale F., Kong W.-p., Akyürek L.M., Ling X., Huang Y., Chakrabarti B.K., et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. JVirol 2003, 77:10078-10087.
53. Belyakov I.M., Ahlers J.D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. JImmunol 2009, 183:6883-6892.
54. Hutchings A.B., Helander A., Silvey K.J., Chandran K., Lucas W.T., Nibert M.L., et al. Secretory immunoglobulin a antibodies against the σ1 Outer Capsid protein of Reovirus type 1 Lang Prevent infection of mouse Peyer's Patches. JVirol 2004, 78:947-957.